Ling Su,
PhD
Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures
Dr. Su is an epidemiologist and drug development professional with 25 years of industry and government experience in the US and Asia. His extensive experience spans the fields of regulatory affairs, medicinal product development strategy, clinical research, drug safety, and pharmacoepidemiology. Dr. Su is currently a Professor and Director of the Institute of Drug Regulatory Science at Shenyang Pharmaceutical University, China and a Venture Partner at Lilly Asia Ventures, based in Shanghai, China. Previously serving as the Strategic Advisor for Life Sciences at Sidley Austin and as Senior Vice President and Head of Development Greater China Region at Novartis, Dr. Su has held various research and development and management positions at Merck, Roche, and Wyeth/Pfizer. Prior to joining the private sector, he worked in the Bureau of Drugs, Ministry of Health in China and in the US FDA’s Center for Drug Evaluation and Research (CDER).
Fellows of DIA
-
Tatsuo Kurokawa,
PhD •Chair, Fellows of DIA
President, Japan Self-Medication Industry -
Martin Harvey Allchurch • Principal International Affairs Officer, European Medicines Agency, European Union
-
Minnie Baylor-Henry,
JD • President, B-Henry & Associates -
Gaby Danan,
MD, PhD • Pharmacovigilance Expert -
Richard Day,
MD • Professor of Clinical Pharmacology, St. Vincent's Hospital -
Marie Dray,
MBA • President, International Regulatory Affairs Group LLC -
Nancy A. Dreyer,
MPH, PhD • Global Chief, Sci Affairs; Sr VP, Head, Center for Advanced Evidence Generation
IQVIA -
Ron Fitzmartin,
PhD • Senior Advisor, Strategic Programs,Center for Drug Evaluation and Research, US Food and Drug Administration -
E. Stewart Geary,
MD • Senior VP, Chief Medical Officer, Director, Corporate Medical Affairs HQ, Eisai Co., Ltd. -
Ken Getz,
MBA • Chairman, CISCRP; Director of Sponsored Research, Tufts Center For the Study of Drug Development -
Alberto Grignolo,
PhD • Corporate Vice President
PAREXEL International -
Yves Juillet,
MD • Senior Vice-President, Industrie Sante -
Sandra L. Kweder,
MD • Deputy Director, FDA Liaison to the EMA, Office of International Programs, OC -
Murray M. Lumpkin,
MD • Deputy Director, Integrated Delivery, and Lead for Global Regulatory Systems Initiatives
Bill and Melinda Gates Foundation -
Sandra A. Milligan,
MD, JD • Senior Vice President, Head of Global Regulatory Affairs and Clinical Safety, Merck & Co., Inc. -
Noriaki Murao,
MS • Representative, NM Consulting -
Jennifer Riggins,
PhD • Advisor, Digital Channels and eCapabilities, Eli Lilly and Company -
Jeffrey Sherman,
MD • Chief Medical Officer & EVP, Horizon Pharma, Inc. -
Per Spindler,
DVM, MBA • Director Biopeople, University of Copenhagen -
Ling Su,
PhD • Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures